FOX NEWS: Your COVID-19 manual: a doctor’s advice on how to treat at home

Play Video

HOUSTON – A doctor wrote a book called the COVID-19 Survival Manual, hoping to help people treat themselves at home and stay out of the hospital, all while his company is trying to develop a nasal spray to help treat it.  

Dr. Steven Quay, President and CEO of Atossa Therapeutics, wants us to understand what he calls three phases of COVID-19. He says the first two phases can usually be treated at home, but the third means a trip to the hospital. The goal is to treat the first two phases at home to prevent your body from slipping into the third phase.

READ MORE ON FOX

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies

Dr. Steven Quay investigates COVID-19's origins, analyzing evidence that suggests SARS-CoV-2 may have resulted from a lab incident rather than natural transmission. Through statistical methods, Dr. Quay estimates a 98% probability of a lab origin, challenging popular theories about animal-to-human transmission and highlighting possible lab safety issues in Wuhan. In this video, he also emphasizes the importance of global safety regulations to prevent future pandemics. Watch to uncover key insights on COVID-19's origins and why lab safety matters for global health.

This video describes the clinical data from the Atossa Therapeutics press release of October 31, 2024 entitled, Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer